Related Experiment Video
Updated: Jun 15, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
[Monoclonal antibody therapy for non-Hodgkin's lymphoma]
Franciane Paul1, Jean-François Rossi, Guillaume Cartron
1Service d'hématologie et centre d'Investigation clinique des biothérapies, CHU de Montpellier, 34295 Montpellier.
Abstract:
Anti-CD20 monoclonal antibodies are currently used for non-Hodgkin's lymphoma treatment and Rituximab (MabThera) and ibritumomab-tiuxetan (Zevalin) currently approved for clinical use. Rituximab has improved survival of patients with follicular and diffuse large B cells lymphoma. Rituximab is safe with uncommon side effects mainly observed during the first infusion. It is basically used associated with chemotherapy every three weeks and also as maintenance therapy for relapsed follicular lymphoma. A better understand of its mechanisms of action has allowed to develop new generation of monoclonal antibody currently tested in clinical trials.
Related Concept Videos
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy

